86,000 Shares of Compass Pathways PLC Sponsored ADR $CMPS Bought by Maxi Investments CY Ltd

Maxi Investments CY Ltd purchased a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 86,000 shares of the company’s stock, valued at approximately $1,070,000.

Other large investors also recently modified their holdings of the company. Ancora Advisors LLC acquired a new stake in Compass Pathways in the second quarter valued at $43,000. EverSource Wealth Advisors LLC lifted its position in shares of Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the period. North Star Investment Management Corp. boosted its holdings in shares of Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares during the period. Finally, WINTON GROUP Ltd boosted its holdings in shares of Compass Pathways by 20.1% in the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock valued at $253,000 after buying an additional 3,000 shares during the period. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Stifel Nicolaus raised their target price on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. BTIG Research lifted their target price on Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Wall Street Zen raised Compass Pathways from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 1st. Finally, Wells Fargo & Company initiated coverage on Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Stock Down 1.2%

Compass Pathways stock opened at $11.05 on Tuesday. The company has a 50-day simple moving average of $13.06 and a 200-day simple moving average of $10.29. The firm has a market capitalization of $1.53 billion, a P/E ratio of -2.39 and a beta of 2.55. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. Compass Pathways PLC Sponsored ADR has a one year low of $4.88 and a one year high of $15.87.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, equities analysts expect that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current year.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.